Anastrozole

This page contains recent news articles, when available, and an overview of Anastrozole but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Anastrozole (when available)

Pharmacology and use:
Anastrozole is a potent and selective non-steroidal aromatase inhibitor indicated for the treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. Many breast cancers have estrogen receptors and growth of these tumors can be stimulated by estrogens. In post-menopausal women, the principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy premenopausally and by use of anti-estrogens and progestational agents both pre- and post-menopausally, and these interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone. For treatment of advanced breast cancer.

Mechanism Of Action:
Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in circulatin estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women.

News Articles on Anastrozole

Hot Flashes, Night Sweats a Good Sign for Breast Cancer Patients  -  Oct 29, 2008
The differences in cancer recurrence rates were seen with both tamoxifen and anastrozole. Overall, patients with and without these symptoms who received Washington Post,

Natco Pharma obtains tentative nod from USFDA for Anastrozole  -  Nov 10, 2008
Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. Natco Pharma is engaged in manufacturing and marketing Myiris.com,

Science and Technology Awareness about breast cancer still low in RP  -  Nov 12, 2008
...manufacturers of breakthrough drugs against breast cancer, including tamoxifen and the new-generation targeted therapy, aromatase inhibitor anastrozole. Philippine Star,

The 2008 Annual American Society of Clinical Oncology Breast ...  -  Nov 18, 2008
...[8] These researchers conducted a clinical trial evaluating the effectiveness of Nexavar® (sorafenib) in addition to Arimidex® (anastrozole) among women Cancer Consultants,

Genomic Health Announces Third Quarter 2008 Financial Results and ...  -  Nov 5, 2008
...using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study" -- "GRB7-dependent pathways Earthtimes (press release),

Health news: Bad side effects that are a blessing, a bacteria to ...  -  Nov 17, 2008
Now Cancer Research UK scientists have found that women who take tamoxifen or the AI drug anastrozole and suffer side effects within three months are 10 per Daily Mail,

Research boosts survival  -  Nov 1, 2008
There are three drugs in this class: anastrozole, letrozole and exemestane. They are used only in post menopausal women. Finally, we have fulvestrant, Malaysia Star,

Breast Cancer Patients Suffering Side Effects from Hormone Therapy ...  -  Nov 6, 2008
...outcomes among women treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole) who experience side effects associated with these therapies. Cancer Consultants,

Why Antiestrogen Side Effects May Predict Decreased Risk of Breast ...  -  Nov 5, 2008
...women who developed hot flashes or night sweats within three months of starting either tamoxifen or anastrozole had a recurrence rate of 18 per cent CTV.ca,

Emerging markets push up AstraZeneca's earnings  -  Oct 31, 2008
Sales of Seroquel (quetiapine) for schizophrenia increased 41% to $1.13 billion, while the breast cancer drug Arimidex (anastrozole) was up 9% to $486 Pharma Times (registration),

研究：新�?��?�预测乳腺癌�?�?�?�?�  -  Nov 13, 2008
...研究人员观察了约四�?��??�?��?妇女�?用Arimidex（�?�俗称的Anastrozole 大纪元

Los sofocos y los sudores nocturnos podrían ser una buena señal ...  -  Nov 1, 2008
Las diferencias en la recurrencia del cáncer se observaron tanto con tamoxifén como con anastrozole. En general, las pacientes con presencia o ausencia de Info7,

�?약청, 한미약품 ‘암로디핀’ 등 10건 임�?승�?�  -  Nov 13, 2008
...아스트�?�제네카는 비-스테로�?�드성 아로마타제 억제제 치료 시 진행�?� �?�후, 국소�?으로 진행�?�/전�?�성 유방암�?� 있는 ER+ve �??경 후 여성�?� 대�?으로 Anastrozole 헬스코리아뉴스,

抗肿瘤�?�物�?�?�治疗领域�?�物总销售冠军  -  Nov 5, 2008
...赛诺�?�-安万特的多西他赛（Docetaxel，泰索�?，Taxotere）和奥沙利铂（Oxaliplatin，�?沙定，Eloxatin）�?阿斯利康的阿那曲唑（Anastrozole 生物通,

Β�?αδινές εξάψεις και ιδ�?ώτας ένδειξη επιτυχημένης θε�?απείας για ...  -  Oct 30, 2008
Οι επιστήμονες εξέτασαν 4.000 γυναίκες που έχουν πε�?άσει εμμηνόπαυση και οι οποίες έπαι�?ναν το φά�?μακο Arimidex, γνωστό και ως αναστ�?οζόλη (anastrozole) ή Newsnow,

Traitement ciblé des sarcomes  -  Nov 14, 2008
...une population de patientes porteuses de sarcome stromal endométrial traitées par des inhibiteurs de l’aromatase (anastrozole et letrosole). Bulletin du Cancer,

Breast cancer awareness  -  20 Oct 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). GoErie.com,

Anastrozole had little or no effect on cognitive function in women ...  -  Oct 1, 2008
Anastrozole did not impair cognitive function in postmenopausal women at high risk for breast cancer in a recently published study. HemOncToday,

Breast Cancer Crisis Over Lack of Volunteers  -  Oct 14, 2008
The worldwide study - IBIS II - is investigating whether a drug called anastrozole could be used to prevent breast cancer in women at high risk of the RedOrbit,

Women Needed For Breast Cancer Prevention Trial, Manchester, England  -  Oct 16, 2008
The aim of the study is to discover if a new drug, anastrozole, can prevent breast cancer if taken daily for five years. The Genesis Appeal is now seeking Medical News Today (press release),

Robin Hood GP in prescription ploy appeals jail time  -  Oct 13, 2008
In the District Court she pleaded guilty to writing false prescriptions for the drug Anastrozole, between August 2002 and November 2004. Courier Mail,

Acupuncture May Help With Side Effects of Hormone Therapy, Study Finds  -  Oct 11, 2008
And drugs called aromatase inhibitors – letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin) -- have been approved to treat both ACS News Center,

Arimidex® Not Associated with Cognitive Impairment Among ...  -  Oct 7, 2008
The use of the aromatase inhibitor Arimidex® (anastrozole) does not appear to be associated with cognitive impairment among postmenopausal women at a high Cancer Consultants,

Update: Thinking and breast cancer  -  Sep 28, 2008
THE QUESTION: Should women who take anastrozole (Arimidex) to deter the growth of cancer cells worry that the medication might affect their mental abilities Nashua Telegraph,

Acupuncture as Good as Drug at Reducing Hot Flashes in Breast Cancer  -  Sep 26, 2008
...who are taking tamoxifen or anastrozole, as presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting. Medscape (subscription)

Battling Breast Cancer  -  Oct 17, 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). Providence Journal,

New Concepts and Therapeutic Approaches for Early-Stage Breast Cancer  -  Oct 17, 2008
Breast Cancer Intervention Study (IBIS) II, which is testing anastrozole, and the MAP.3 research study, which will compare exemestane with placebo. Medscape (subscription)

Nexavar® May Overcome Resistance to Arimidex® in Breast Cancer  -  Oct 10, 2008
Researchers from Georgetown University have reported that the addition of Nexavar® (sorafenib) to Arimidex® (anastrozole) helps restore sensitivity to Cancer Consultants,

Novel model may predict the need for adjuvant therapy in ER ...  -  Oct 6, 2008
They tested and validated the model using data from the IMPACT trial, a 203-person trial that compared anastrozole vs. tamoxifen or both for three months HemOncToday,

Delayed Adjuvant Chemotherapy in Breast Cancer  -  Sep 30, 2008
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with Medscape (subscription)

Many women not adhering to breast cancer therapy  -  Sep 27, 2008
In fact, it has recently been shown that treatments such as anastrozole, an anti-estrogen therapy, continue to work for years after treatment is completed, The North Bay Nugget,

Some breast cancer patients may benefit from acupuncture  -  Sep 24, 2008
The treatments were tested for 12 weeks in 47 patients who were receiving either Tamoxifen or Arimidex (Anastrozole) for breast cancer and were experiencing Cancer Research UK - News & Resources,

Geen compensatie voor kankerpatiënten met hormoongevoelige medicatie  -  Oct 6, 2008
...(Tamoxifen) letrozole (Femara), exemestane (Aromasin) en anastrozole (Arimidex) ook op de lijst van medicijnen zou staan. Dit blijkt niet het geval. Nieuwsbank (abonnement),

Postmenopausal women taking anastrozole as a chemopreventive ...  Sep 5, 2008
The aim of the cognitive sub-study was to compare the effect of anastrozole on memory and attention in women enrolled in the IBIS-II breast cancerPhysOrg.com,

Breast Cancer Drug Not Tied to Cognitive Decline: Study  Sep 2, 2008
2 (HealthDay News) -- Contrary to previous study results, the cancer prevention drug anastrozole does not appear to cause impairment of cognitiveWashington Post,

GU Med. Center Research May Make Cancer More Treatable  Sep 12, 2008
Current results show a clinical benefit in 26 percent of the women in the study who received both the drugs sorafenib and anastrozole.Georgetown University The Hoya,

Anastrozole Does Not Impair Cognitive Performance in ...  Sep 2, 2008
NEW YORK -- September 2, 2008 -- Daily anastrozole therapy given to postmenopausal women who are at high risk of breast cancer, with the intention ofDG News

Drug Re-Sensitizes Breast Tumors to Treatment  Sep 5, 2008
Preliminary analysis of study data showed that 26 percent of the women showed a clinical benefit response while taking both sorafenib and anastrozole.Washington Post,

No Cognition Risks Seen for Breast Cancer Prophylaxis with ...  Sep 3, 2008
Explain to interested patients that this study found no evidence that hormonal therapy with anastrozole to prevent breast cancer does not appear to have anMedPage Today,

Outsmarting Breast Cancer  Sep 8, 2008
Researchers added another drug, called sorafenib, to their treatment to see if it might combine with anastrozole to have a positive effect.Ivanhoe,

Risk factors for joint symptoms identified  Aug 27, 2008
Previous hormone therapy, hormone receptor positivity, previous chemotherapy, obesity and treatment with anastrozole were risk factors for joint symptoms inHemOncToday,

No Mental Effects Seen with Arimidex  Sep 3, 2008
..."These findings should be reassuring in the short term for postmenopausal women being treated with anastrozole, their clinicians, and carers," lead authorCancerpage.com,

ASCO Breast: Targeted Therapy May Restore Endocrine Sensitivity to ...  Sep 8, 2008
All patients received sorafenib 400 mg twice daily plus a standard dose of anastrozole. Of the 27 patients two had partial responses that lasted more thanMedPage Today,

New approach to "re-sensitize" treatment resistant tumours  Sep 6, 2008
The preliminary results have shown clinical benefit response in 26 percent of the patients taking both sorafenib and anastrozole. "Given what we know aboutEconomic Times,

Looking for a cancer cure in all the wrong places  Sep 10, 2008
...into a study comparing the efficacy of flaxseed vs. the aromatase inhibitor anastrozole (Arimidex, AstraZeneca) to treat ER-positive breast cancer.HemOncToday,

Zoledronic Acid Protects Bones of Women Getting Breast Cancer ...  Aug 19, 2008
...to receive three years of either goserelin plus tamoxifen with or without zoledronic acid or goserelin plus anastrozole with or without zoledronic acid.Washington Post,

Zometa® Helps Prevent Bone Loss in Early Breast Cancer  Aug 29, 2008
However, some types of endocrine therapy, such as aromatase inhibitors (Arimidex® [anastrozole], Femara® [letrozole]) are associated with a loss of boneCancer Consultants,

Zoledronic Acid Improves Bone-Mineral Density Loss In ...  Aug 26, 2008
...premenopausal women were randomized to receive one of two endocrine therapies, either 3 years of goserelin plus tamoxifen or goserelin plus anastrozole.Medical News Today,

My quest for the holy grail of breast cancer treatment  Aug 22, 2008
I think my cats are getting just a little tired of hearing me try to pronounce things like "armamentarium" and drugs such as letrozole, anastrozole andThe Kingston Whig-Standard,

Zoledronate prevents bone loss during endocrine treatment for ...  Aug 21, 2008
...plus tamoxifen or anastrozole, with or without zoledronic acid in premenopausal women with early-stage, hormone-receptor-positive breast cancer.Medicexchange,

Bisphosphonate Thwarts Bone Loss from Breast Cancer Endocrine Therapy  Aug 20, 2008
The patients were randomized to three years of treatment with goserelin plus anastrozole (Aromasin) or tamoxifen. Patients in both groups were furtherMedPage Today,

Zoledronic acid for bone density  Aug 20, 2008
...to receive 3 years of either goserelin plus tamoxifen with or without zoledronic acid or goserelin plus anastrozole with or without zoldronic acid.ecancermedicalscience,

Endocrine Therapy Plus Zoledronic Acid Improves BMD in ...  Aug 19, 2008
3-year treatment of either goserelin plus tamoxifen with or without zoledronic acid or goserelin plus anastrozole with or without zoledronic acid.DG News

El fármaco Arimidex no produce efectos mentales adversos  Sep 3, 2008
Arimidex (anastrozole) pertenece a una clase de medicamentos llamada inhibidores de la aromatasa, que interrumpen la producción de estrógeno.Buena Salud

아나스트로졸, �?�지능력 �?�?하지 않아  Sep 2, 2008
...아리미�?스�?� 성분�?� 아나스트로졸(anastrozole). 타목시펜(tamoxifen)보다 유방암 재발 방지 효과가 우수한 것으로 알려져 있다. �?�전�?� 연구�?서 아나스트로졸 복용메디게�?�트뉴스,

Meta-analysis of trials comparing anastrozole and tamoxifen for ...  -  Jul 29, 2008
ObjectiveIt was aimed to review the literature and make a meta-analysis of the trials on both upfront, switching, and sequencing anastrozole in the adjuvant 7thSpace Interactive (press release),

The Aromatase Inhibitor Anastrozole Is Ineffective in the ...  -  Jul 10, 2008
The use of anastrozole for the treatment of PP in this condition has not been well studied. Objective: The objective of the study was to determine the Journal of Clinical Endocrinology and Metabolism,

Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug ...  -  Jul 17, 2008
The Phase IIb dose ranging trial will include three treatment arms of anastrozole, all with a fixed dose oral contraceptive in pre-menopausal women Earthtimes (press release),

New Treatment Strategies Provide More Options for Patients With ...  -  Jul 22, 2008
Trial participants were treated with the hormone therapies tamoxifen or anastrozole, with or without zoledronic acid. Tamoxifen is currently given as a Journal of American Medical Association (subscription),

BREAKING NEWS: AstraZeneca earnings up as Crestor sales soar  -  Jul 31, 2008
Sales of Seroquel (quetiapine) for schizophrenia increased 11% to $1.11 billion, while the breast cancer drug Arimidex (anastrozole) was up 6% to $490 Pharma Times (subscription),

OFF THE TURNBUCKLE: Raw-ECW merger plans have been scrapped  -  Jul 26, 2008
Specifically, anti-estrogens, such as Anastrozole, were added to the list. This drug is used to mask one of the side-effects of steroid use, The Morning Journal,

«سيدتي» تواكب المؤتمر السنوي للجمعية الأميركية لعلاج السرطان  -  Jul 14, 2008
وكان الدواءان «اناستروزول» Anastrozole و«تاموكسي�?ين» Tamoxifen، مع توقي�? الحيض متطابقين من حيث النتائج الممتازة بدون علاج كيميائي. سـيّدتي,

Brand Names/Synonyms:
Anastrozole is also known by the following brand names and/or synonymsAnastrole; Anastrozol; Anastrozole; Anastrozole [Usan:Ban:Inn]; Arimidex; CHEMBANK1630; ICI-D 1033; ZD 1033

Drug Category:
Anastrozole is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BG03

Dosage Forms:
tablets containing 1mg anastrozole

Absorption:
Absorbed into the systemic cirulation, and food does not affect the extent of absorption.

Interactions:
-->Interactions for Anastrozole:

Anastrozole inhibited in vitro metabolic reactions catalyzed by cytochromes P450 1A2, 2C8/9, and 3A4 but only at relatively high concentrations. Anastrozole did not inhibit P450 2A6 or the polymorphic P450 2D6 in human liver microsomes. Anastrozole did not alter the pharmacokinetics of antipyrine. Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.

An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.

At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation. This treatment arm was discontinued from the trial. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY ñ Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections). Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.

Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

Drug/Laboratory Test Interactions

No clinically significant changes in the results of clinical laboratory tests have been observed.

-->

Chemical IUPAC Name:
2-[3-(1-cyano-1-methyl-ethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methyl-propanenitrile

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.